{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:39:45Z","timestamp":1794613185843,"version":"4.9.1"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Chimeric antigen receptor (CAR) represents a novel targeted therapy that uses genetic engineering to modify effector cells for precise tumor cell targeting. Chimeric antigen receptor-T (CAR-T) cell immunotherapy, which employs T cells as effectors, has demonstrated significant efficacy in treating hematologic malignancies. However, its efficacy against solid tumors remains inadequate and is accompanied by toxic side effects, including cytokine release syndrome, neurotoxicity and on-target\/off-tumor effects. In contrast to T cells, natural killer (NK) cells exhibit a broader source range and can non-specifically lyse tumor cells. Moreover, it can also reduce toxicity and side effects to some extent. This review comprehensively examines recent research progress on CAR-NK therapy for solid tumors, encompassing both in vivo and in vitro studies, with a focus on CAR-NK cell design and production methods. Drawing upon laboratory and clinical evidence, this review summarizes the current challenges and side effects associated with CAR-NK technology.<\/jats:p>","DOI":"10.1007\/s00262-025-04106-z","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T14:06:15Z","timestamp":1753365975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Precision sniper for solid tumors: CAR-NK cell therapy"],"prefix":"10.1007","volume":"74","author":[{"given":"Sisi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enjie","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenya","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqiang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"4106_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cells8050472","author":"S Stoiber","year":"2019","unstructured":"Stoiber S, Cadilha BL, Benmebarek MR et al (2019) Limitations in the design of chimeric antigen receptors for cancer therapy. Cells. https:\/\/doi.org\/10.3390\/cells8050472","journal-title":"Cells"},{"issue":"1","key":"4106_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong Y, Klein Wolterink RGJ, Wang J et al (2021) Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol 14(1):73. https:\/\/doi.org\/10.1186\/s13045-021-01083-5","journal-title":"J Hematol Oncol"},{"issue":"6","key":"4106_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P et al (2020) Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med 382(6):545\u2013553. https:\/\/doi.org\/10.1056\/NEJMoa1910607","journal-title":"N Engl J Med"},{"issue":"15","key":"4106_CR4","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/jco.20.02262","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah NN, Lee DW, Yates B et al (2021) Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol 39(15):1650\u20131659. https:\/\/doi.org\/10.1200\/jco.20.02262","journal-title":"J Clin Oncol"},{"issue":"7926","key":"4106_CR5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","volume":"609","author":"J Zhang","year":"2022","unstructured":"Zhang J, Hu Y, Yang J et al (2022) Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature 609(7926):369\u2013374. https:\/\/doi.org\/10.1038\/s41586-022-05140-y","journal-title":"Nature"},{"key":"4106_CR6","doi-asserted-by":"publisher","first-page":"1410519","DOI":"10.3389\/fimmu.2024.1410519","volume":"15","author":"J Jing","year":"2024","unstructured":"Jing J, Ma Y, Xie Z et al (2024) Acute T-cell lymphoblastic leukemia: chimeric antigen receptor technology may offer a new hope. Front Immunol 15:1410519. https:\/\/doi.org\/10.3389\/fimmu.2024.1410519","journal-title":"Front Immunol"},{"issue":"1","key":"4106_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert ML, Schmitt M, Wang L et al (2021) Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol 32(1):34\u201348. https:\/\/doi.org\/10.1016\/j.annonc.2020.10.478","journal-title":"Ann Oncol"},{"issue":"1","key":"4106_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","volume":"14","author":"S Liu","year":"2021","unstructured":"Liu S, Galat V, Galat Y et al (2021) NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol 14(1):7. https:\/\/doi.org\/10.1186\/s13045-020-01014-w","journal-title":"J Hematol Oncol"},{"issue":"2","key":"4106_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/ijc.2910160205","volume":"16","author":"RB Herberman","year":"1975","unstructured":"Herberman RB, Nunn ME, Holden HT et al (1975) Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 16(2):230\u2013239. https:\/\/doi.org\/10.1002\/ijc.2910160205","journal-title":"Int J Cancer"},{"key":"4106_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102975","volume":"59","author":"G Xie","year":"2020","unstructured":"Xie G, Dong H, Liang Y et al (2020) CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine 59:102975. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102975","journal-title":"EBioMedicine"},{"issue":"9","key":"4106_CR11","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/cyto.a.24001","volume":"97","author":"G Del Zotto","year":"2020","unstructured":"Del Zotto G, Antonini F, Pesce S et al (2020) Comprehensive phenotyping of human PB NK cells by flow cytometry. Cytometry A 97(9):891\u2013899. https:\/\/doi.org\/10.1002\/cyto.a.24001","journal-title":"Cytometry A"},{"issue":"4","key":"4106_CR12","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","volume":"126","author":"A Poli","year":"2009","unstructured":"Poli A, Michel T, Th\u00e9r\u00e9sine M et al (2009) CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 126(4):458\u2013465. https:\/\/doi.org\/10.1111\/j.1365-2567.2008.03027.x","journal-title":"Immunology"},{"issue":"6","key":"4106_CR13","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/(sici)1097-0215(19990315)80:6<880::aid-ijc14>3.0.co;2-y","volume":"80","author":"S Ben-Eliyahu","year":"1999","unstructured":"Ben-Eliyahu S, Page GG, Yirmiya R et al (1999) Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int J Cancer 80(6):880\u2013888. https:\/\/doi.org\/10.1002\/(sici)1097-0215(19990315)80:6%3c880::aid-ijc14%3e3.0.co;2-y","journal-title":"Int J Cancer"},{"issue":"6","key":"4106_CR14","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1128\/iai.65.6.2283-2291.1997","volume":"65","author":"T Hensler","year":"1997","unstructured":"Hensler T, Hecker H, Heeg K et al (1997) Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun 65(6):2283\u20132291. https:\/\/doi.org\/10.1128\/iai.65.6.2283-2291.1997","journal-title":"Infect Immun"},{"issue":"8","key":"4106_CR15","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1245\/aso.2003.02.007","volume":"10","author":"G Shakhar","year":"2003","unstructured":"Shakhar G, Ben-Eliyahu S (2003) Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol 10(8):972\u2013992. https:\/\/doi.org\/10.1245\/aso.2003.02.007","journal-title":"Ann Surg Oncol"},{"key":"4106_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101073","volume":"60","author":"A Merino","year":"2023","unstructured":"Merino A, Maakaron J, Bachanova V (2023) Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting. Blood Rev 60:101073. https:\/\/doi.org\/10.1016\/j.blre.2023.101073","journal-title":"Blood Rev"},{"issue":"8","key":"4106_CR17","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS, Soignier Y, Panoskaltsis-Mortari A et al (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105(8):3051\u20133057. https:\/\/doi.org\/10.1182\/blood-2004-07-2974","journal-title":"Blood"},{"issue":"3","key":"4106_CR18","first-page":"429","volume":"84","author":"A Vacca","year":"1991","unstructured":"Vacca A, Di Stefano R, Frassanito A et al (1991) A disturbance of the IL-2\/IL-2 receptor system parallels the activity of multiple myeloma. Clin Exp Immunol 84(3):429\u2013434","journal-title":"Clin Exp Immunol"},{"key":"4106_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00091","volume":"7","author":"H Klingemann","year":"2016","unstructured":"Klingemann H, Boissel L, Toneguzzo F (2016) Natural killer cells for immunotherapy - advantages of the NK-92 cell line over blood NK cells. Front Immunol 7:91. https:\/\/doi.org\/10.3389\/fimmu.2016.00091","journal-title":"Front Immunol"},{"key":"4106_CR20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230903","author":"M Ayala Ceja","year":"2024","unstructured":"Ayala Ceja M, Khericha M, Harris CM et al (2024) CAR-T cell manufacturing: major process parameters and next-generation strategies. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20230903","journal-title":"J Exp Med"},{"issue":"6","key":"4106_CR21","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying Z, Huang XF, Xiang X et al (2019) A safe and potent anti-CD19 CAR T cell therapy. Nat Med 25(6):947\u2013953. https:\/\/doi.org\/10.1038\/s41591-019-0421-7","journal-title":"Nat Med"},{"issue":"11","key":"4106_CR22","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","volume":"25","author":"L Alabanza","year":"2017","unstructured":"Alabanza L, Pegues M, Geldres C et al (2017) Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. J Mole Ther. 25(11):2452\u20132465","journal-title":"J Mole Ther."},{"issue":"2","key":"4106_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"Li Y, Hermanson DL, Moriarity BS et al (2018) Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell 23(2):181-192.e5. https:\/\/doi.org\/10.1016\/j.stem.2018.06.002","journal-title":"Cell Stem Cell"},{"issue":"7","key":"4106_CR24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.65291","volume":"16","author":"SK Ghorai","year":"2024","unstructured":"Ghorai SK, Pearson AN (2024) Current strategies to improve chimeric antigen receptor T (CAR-T) cell persistence. Cureus 16(7):e65291. https:\/\/doi.org\/10.7759\/cureus.65291","journal-title":"Cureus"},{"issue":"2","key":"4106_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41587-019-0329-2","volume":"38","author":"M MacKay","year":"2020","unstructured":"MacKay M, Afshinnekoo E, Rub J et al (2020) The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat Biotechnol 38(2):233\u2013244. https:\/\/doi.org\/10.1038\/s41587-019-0329-2","journal-title":"Nat Biotechnol"},{"issue":"9","key":"4106_CR26","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1182\/bloodadvances.2020001510","volume":"4","author":"X Wang","year":"2020","unstructured":"Wang X, Jasinski DL, Medina JL et al (2020) Inducible MyD88\/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells. Blood Adv 4(9):1950\u20131964. https:\/\/doi.org\/10.1182\/bloodadvances.2020001510","journal-title":"Blood Adv"},{"issue":"2","key":"4106_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/aps.2017.125","volume":"39","author":"Y Hu","year":"2018","unstructured":"Hu Y, Tian ZG, Zhang C (2018) Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Acta Pharmacol Sin 39(2):167\u2013176. https:\/\/doi.org\/10.1038\/aps.2017.125","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"4106_CR28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/jleuko\/qiad074","volume":"114","author":"T Bexte","year":"2023","unstructured":"Bexte T, Reindl LM, Ullrich E (2023) Nonviral technologies can pave the way for CAR-NK cell therapy. J Leukoc Biol 114(5):475\u2013486. https:\/\/doi.org\/10.1093\/jleuko\/qiad074","journal-title":"J Leukoc Biol"},{"issue":"9","key":"4106_CR29","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1172\/JCI35700","volume":"118","author":"S Hacein-Bey-Abina","year":"2008","unstructured":"Hacein-Bey-Abina S, Garrigue A, Wang GP et al (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J clin investig 118(9):3132\u20133142","journal-title":"J clin investig"},{"key":"4106_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-29","volume":"10","author":"Z Zheng","year":"2012","unstructured":"Zheng Z, Chinnasamy N, Morgan RA (2012) Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry. J Transl Med 10:29. https:\/\/doi.org\/10.1186\/1479-5876-10-29","journal-title":"J Transl Med"},{"key":"4106_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113208","author":"N Schanda","year":"2021","unstructured":"Schanda N, Sauer T, Kunz A et al (2021) Sensitivity and specificity of CD19.CAR-T cell detection by flow cytometry and PCR. Cells. https:\/\/doi.org\/10.3390\/cells10113208","journal-title":"Cells"},{"issue":"2","key":"4106_CR32","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/imm.13624","volume":"169","author":"L Chen","year":"2023","unstructured":"Chen L, Liu S, Adah D et al (2023) Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma. Immunology 169(2):204\u2013218. https:\/\/doi.org\/10.1111\/imm.13624","journal-title":"Immunology"},{"key":"4106_CR33","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/978-1-4939-3684-7_14","volume":"1441","author":"MT Phan","year":"2016","unstructured":"Phan MT, Lee SH, Kim SK et al (2016) Expansion of NK cells using genetically engineered K562 feeder cells. Methods Mol Biol 1441:167\u2013174. https:\/\/doi.org\/10.1007\/978-1-4939-3684-7_14","journal-title":"Methods Mol Biol"},{"issue":"3","key":"4106_CR34","doi-asserted-by":"publisher","first-page":"676","DOI":"10.4049\/jimmunol.1801137","volume":"203","author":"L Vidard","year":"2019","unstructured":"Vidard L, Dureuil C, Baudhuin J et al (2019) CD137 (4\u20131BB) engagement fine-tunes synergistic IL-15- and IL-21-driven NK cell proliferation. J Immunol 203(3):676\u2013685. https:\/\/doi.org\/10.4049\/jimmunol.1801137","journal-title":"J Immunol"},{"issue":"180","key":"4106_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3791\/62336","volume":"8","author":"M Ma","year":"2022","unstructured":"Ma M, Badeti S, Kim JK et al (2022) Natural Killer (NK) and CAR-NK cell expansion method using membrane bound-IL-21-modified B cell line. J Vis Exp 8(180):10\u20133791. https:\/\/doi.org\/10.3791\/62336","journal-title":"J Vis Exp"},{"issue":"9","key":"4106_CR36","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.21873\/anticanres.16577","volume":"43","author":"DY Lee","year":"2023","unstructured":"Lee DY, Kim Y, Park JS et al (2023) Development of genetically engineered feeder cells for natural killer cell expansion. Anticancer Res 43(9):3897\u20133904. https:\/\/doi.org\/10.21873\/anticanres.16577","journal-title":"Anticancer Res"},{"issue":"5","key":"4106_CR37","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40259-021-00494-7","volume":"35","author":"X Yao","year":"2021","unstructured":"Yao X, Matosevic S (2021) Cryopreservation of NK and T cells without DMSO for adoptive cell-based immunotherapy. BioDrugs 35(5):529\u2013545. https:\/\/doi.org\/10.1007\/s40259-021-00494-7","journal-title":"BioDrugs"},{"issue":"2","key":"4106_CR38","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1021\/acs.molpharmaceut.3c00798","volume":"21","author":"S Das","year":"2024","unstructured":"Das S, Niemeyer E, Leung ZA et al (2024) Human natural killer cells cryopreserved without DMSO sustain robust effector responses. Mol Pharm 21(2):651\u2013660. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00798","journal-title":"Mol Pharm"},{"key":"4106_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.imlet.2017.09.012","volume":"192","author":"S Pasley","year":"2017","unstructured":"Pasley S, Zylberberg C, Matosevic S (2017) Natural killer-92 cells maintain cytotoxic activity after long-term cryopreservation in novel DMSO-free media. Immunol Lett 192:35\u201341. https:\/\/doi.org\/10.1016\/j.imlet.2017.09.012","journal-title":"Immunol Lett"},{"key":"4106_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cryobiol.2023.104835","volume":"114","author":"R Xu","year":"2024","unstructured":"Xu R, Shi X, Huang H et al (2024) Development of a Me(2)SO-free cryopreservation medium and its long-term cryoprotection on the CAR-NK cells. Cryobiology 114:104835. https:\/\/doi.org\/10.1016\/j.cryobiol.2023.104835","journal-title":"Cryobiology"},{"issue":"1","key":"4106_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47574-0","volume":"15","author":"A Berjis","year":"2024","unstructured":"Berjis A, Muthumani D, Aguilar OA et al (2024) Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation. Nat Commun 15(1):3937. https:\/\/doi.org\/10.1038\/s41467-024-47574-0","journal-title":"Nat Commun"},{"issue":"1","key":"4106_CR42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4106_CR43","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.dld.2015.11.001","volume":"48","author":"N Le","year":"2016","unstructured":"Le N, Sund M, Vinci A (2016) Prognostic and predictive markers in pancreatic adenocarcinoma. Dig Liver Dis 48(3):223\u2013230. https:\/\/doi.org\/10.1016\/j.dld.2015.11.001","journal-title":"Dig Liver Dis"},{"issue":"4","key":"4106_CR44","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1053\/j.gastro.2021.12.281","volume":"162","author":"KY Teng","year":"2022","unstructured":"Teng KY, Mansour AG, Zhu Z et al (2022) Off-the-shelf prostate stem cell antigen-directed chimeric antigen receptor natural killer cell therapy to treat pancreatic cancer. Gastroenterology 162(4):1319\u20131333. https:\/\/doi.org\/10.1053\/j.gastro.2021.12.281","journal-title":"Gastroenterology"},{"key":"4106_CR45","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.molimm.2017.03.017","volume":"85","author":"S Zuo","year":"2017","unstructured":"Zuo S, Wen Y, Panha H et al (2017) Modification of cytokine-induced killer cells with folate receptor alpha (FR\u03b1)-specific chimeric antigen receptors enhances their antitumor immunity toward FR\u03b1-positive ovarian cancers. Mol Immunol 85:293\u2013304. https:\/\/doi.org\/10.1016\/j.molimm.2017.03.017","journal-title":"Mol Immunol"},{"key":"4106_CR46","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jconrel.2020.07.016","volume":"326","author":"YE Lee","year":"2020","unstructured":"Lee YE, Ju A, Choi HW et al (2020) Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment. J Control Release 326:310\u2013323. https:\/\/doi.org\/10.1016\/j.jconrel.2020.07.016","journal-title":"J Control Release"},{"issue":"6","key":"4106_CR47","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.stem.2024.03.018","volume":"31","author":"Z Shah","year":"2024","unstructured":"Shah Z, Tian L, Li Z et al (2024) Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer. Cell Stem Cell 31(6):803-817.e6. https:\/\/doi.org\/10.1016\/j.stem.2024.03.018","journal-title":"Cell Stem Cell"},{"issue":"11","key":"4106_CR48","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.Cd-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli PS, Zauderer MG, Rivi\u00e8re I et al (2021) A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov 11(11):2748\u20132763. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-0407","journal-title":"Cancer Discov"},{"issue":"11","key":"4106_CR49","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","volume":"27","author":"AR Haas","year":"2019","unstructured":"Haas AR, Tanyi JL, O\u2019Hara MH et al (2019) Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol Ther 27(11):1919\u20131929. https:\/\/doi.org\/10.1016\/j.ymthe.2019.07.015","journal-title":"Mol Ther"},{"issue":"2","key":"4106_CR50","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1158\/2159-8290.Cd-15-0583","volume":"6","author":"A Morello","year":"2016","unstructured":"Morello A, Sadelain M, Adusumilli PS (2016) Mesothelin-targeted CARs: Driving T cells to solid tumors. Cancer Discov 6(2):133\u2013146. https:\/\/doi.org\/10.1158\/2159-8290.Cd-15-0583","journal-title":"Cancer Discov"},{"issue":"7","key":"4106_CR51","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41419-019-1711-1","volume":"10","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Jiang D, Yang H et al (2019) Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor. Cell Death Dis 10(7):476. https:\/\/doi.org\/10.1038\/s41419-019-1711-1","journal-title":"Cell Death Dis"},{"issue":"1","key":"4106_CR52","doi-asserted-by":"publisher","first-page":"2054105","DOI":"10.1080\/2162402x.2022.2054105","volume":"11","author":"Y Da","year":"2022","unstructured":"Da Y, Liu Y, Hu Y et al (2022) STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer. Oncoimmunology 11(1):2054105. https:\/\/doi.org\/10.1080\/2162402x.2022.2054105","journal-title":"Oncoimmunology"},{"key":"4106_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101611","author":"T Flieswasser","year":"2019","unstructured":"Flieswasser T, Camara-Clayette V, Danu A et al (2019) Screening a broad range of solid and haematological tumour types for CD70 expression using a uniform IHC methodology as potential patient stratification method. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11101611","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4106_CR54","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s10142-023-00977-6","volume":"23","author":"F Kong","year":"2023","unstructured":"Kong F, Ye Q, Xiong Y (2023) Comprehensive analysis of prognosis and immune function of CD70-CD27 signaling axis in pan-cancer. Funct Integr Genomics 23(1):48. https:\/\/doi.org\/10.1007\/s10142-023-00977-6","journal-title":"Funct Integr Genomics"},{"issue":"17","key":"4106_CR55","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.7150\/thno.43991","volume":"10","author":"M Yang","year":"2020","unstructured":"Yang M, Tang X, Zhang Z et al (2020) Tandem CAR-T cells targeting CD70 and B7\u2013H3 exhibit potent preclinical activity against multiple solid tumors. Theranostics 10(17):7622\u20137634. https:\/\/doi.org\/10.7150\/thno.43991","journal-title":"Theranostics"},{"issue":"1","key":"4106_CR56","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13045-024-01525-w","volume":"17","author":"A Van den Eynde","year":"2024","unstructured":"Van den Eynde A, Gehrcken L, Verhezen T et al (2024) IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts. J Hematol Oncol 17(1):8. https:\/\/doi.org\/10.1186\/s13045-024-01525-w","journal-title":"J Hematol Oncol"},{"key":"4106_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106535","volume":"84","author":"K Barzaman","year":"2020","unstructured":"Barzaman K, Karami J, Zarei Z et al (2020) Breast cancer: biology, biomarkers, and treatments. Int Immunopharmacol 84:106535. https:\/\/doi.org\/10.1016\/j.intimp.2020.106535","journal-title":"Int Immunopharmacol"},{"key":"4106_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15071987","author":"MF Mercogliano","year":"2023","unstructured":"Mercogliano MF, Bruni S, Mauro FL et al (2023) Emerging targeted therapies for HER2-positive breast cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15071987","journal-title":"Cancers (Basel)"},{"issue":"9","key":"4106_CR59","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nrc2713","volume":"9","author":"EA Musgrove","year":"2009","unstructured":"Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9(9):631\u2013643. https:\/\/doi.org\/10.1038\/nrc2713","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"4106_CR60","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1080\/14656566.2019.1651293","volume":"20","author":"M Soleja","year":"2019","unstructured":"Soleja M, Raj GV, Unni N (2019) An evaluation of fulvestrant for the treatment of metastatic breast cancer. Expert Opin Pharmacother 20(15):1819\u20131829. https:\/\/doi.org\/10.1080\/14656566.2019.1651293","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"4106_CR61","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/annonc\/mdm170","volume":"18","author":"M Beeram","year":"2007","unstructured":"Beeram M, Tan QT, Tekmal RR et al (2007) Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 18(8):1323\u20131328. https:\/\/doi.org\/10.1093\/annonc\/mdm170","journal-title":"Ann Oncol"},{"issue":"7","key":"4106_CR62","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1078-0432.Ccr-13-2332","volume":"20","author":"R Jeselsohn","year":"2014","unstructured":"Jeselsohn R, Yelensky R, Buchwalter G et al (2014) Emergence of constitutively active estrogen receptor-\u03b1 mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res 20(7):1757\u20131767. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-2332","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4106_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2883","volume":"13","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Moerkens M, Ramaiahgari S et al (2011) Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK\/ERK and PI3K\/Akt signaling routes. Breast Cancer Res 13(3):R52. https:\/\/doi.org\/10.1186\/bcr2883","journal-title":"Breast Cancer Res"},{"key":"4106_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00909","volume":"10","author":"AD Barrow","year":"2019","unstructured":"Barrow AD, Martin CJ, Colonna M (2019) The natural cytotoxicity receptors in health and disease. Front Immunol 10:909. https:\/\/doi.org\/10.3389\/fimmu.2019.00909","journal-title":"Front Immunol"},{"issue":"9","key":"4106_CR65","first-page":"4455","volume":"11","author":"YZ Lin","year":"2021","unstructured":"Lin YZ, Lee CC, Cho DY et al (2021) Suppression of breast cancer cells resistant to a pure anti-estrogen with CAR-transduced natural killer cells. Am J Cancer Res 11(9):4455\u20134469","journal-title":"Am J Cancer Res"},{"key":"4106_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24109038","author":"MJ Raftery","year":"2023","unstructured":"Raftery MJ, Franz\u00e9n AS, Radecke C et al (2023) Next generation CD44v6-specific CAR-NK cells effective against triple negative breast cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24109038","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4106_CR67","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1038\/s41598-020-59736-3","volume":"10","author":"Z Hu","year":"2020","unstructured":"Hu Z (2020) Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer. Sci Rep 10(1):2815. https:\/\/doi.org\/10.1038\/s41598-020-59736-3","journal-title":"Sci Rep"},{"key":"4106_CR68","doi-asserted-by":"publisher","first-page":"1254821","DOI":"10.3389\/fimmu.2023.1254821","volume":"14","author":"N Murali Shankar","year":"2023","unstructured":"Murali Shankar N, Ortiz-Montero P, Kurzyukova A et al (2023) Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer. Front Immunol 14:1254821. https:\/\/doi.org\/10.3389\/fimmu.2023.1254821","journal-title":"Front Immunol"},{"issue":"1","key":"4106_CR69","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/bf02968000","volume":"11","author":"J Kurebayashi","year":"2004","unstructured":"Kurebayashi J, Okubo S, Yamamoto Y et al (2004) Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer. Breast Cancer 11(1):38\u201341. https:\/\/doi.org\/10.1007\/bf02968000","journal-title":"Breast Cancer"},{"key":"4106_CR70","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-23-1017","author":"Y Liu","year":"2024","unstructured":"Liu Y, Chen J, Tian J et al (2024) Engineered CAR-NK cells with tolerance to H2O2 and hypoxia can suppress postoperative relapse of triple-negative breast cancers. Cancer Immunol Res. https:\/\/doi.org\/10.1158\/2326-6066.Cir-23-1017","journal-title":"Cancer Immunol Res"},{"key":"4106_CR71","doi-asserted-by":"publisher","DOI":"10.1172\/jci163446","author":"F Khan","year":"2023","unstructured":"Khan F, Pang L, Dunterman M et al (2023) Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy. J Clin Invest. https:\/\/doi.org\/10.1172\/jci163446","journal-title":"J Clin Invest"},{"issue":"5","key":"4106_CR72","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/glia.23520","volume":"67","author":"M Brandao","year":"2019","unstructured":"Brandao M, Simon T, Critchley G et al (2019) Astrocytes, the rising stars of the glioblastoma microenvironment. Glia 67(5):779\u2013790. https:\/\/doi.org\/10.1002\/glia.23520","journal-title":"Glia"},{"key":"4106_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/srep11483","volume":"5","author":"J Han","year":"2015","unstructured":"Han J, Chu J, Chan WK et al (2015) CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci Rep 5:11483. https:\/\/doi.org\/10.1038\/srep11483","journal-title":"Sci Rep"},{"issue":"7","key":"4106_CR74","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1182\/blood-2010-01-043737","volume":"116","author":"B Jena","year":"2010","unstructured":"Jena B, Dotti G, Cooper LJ (2010) Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116(7):1035\u20131044. https:\/\/doi.org\/10.1182\/blood-2010-01-043737","journal-title":"Blood"},{"issue":"4","key":"4106_CR75","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1158\/1078-0432.Ccr-13-0709","volume":"20","author":"JH Sampson","year":"2014","unstructured":"Sampson JH, Choi BD, Sanchez-Perez L et al (2014) EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res 20(4):972\u2013984. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-0709","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4106_CR76","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/cji.0000000000000082","volume":"38","author":"N M\u00fcller","year":"2015","unstructured":"M\u00fcller N, Michen S, Tietze S et al (2015) Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12\/SDF-1\u03b1-secreting glioblastoma. J Immunother 38(5):197\u2013210. https:\/\/doi.org\/10.1097\/cji.0000000000000082","journal-title":"J Immunother"},{"issue":"5","key":"4106_CR77","doi-asserted-by":"publisher","first-page":"djv375","DOI":"10.1093\/jnci\/djv375","volume":"108","author":"C Zhang","year":"2016","unstructured":"Zhang C, Burger MC, Jennewein L et al (2016) ErbB2\/HER2-specific NK cells for targeted therapy of glioblastoma. J Natl Cancer Inst 108(5):djv375. https:\/\/doi.org\/10.1093\/jnci\/djv375","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"4106_CR78","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","volume":"25","author":"MC Burger","year":"2023","unstructured":"Burger MC, Forster MT, Romanski A et al (2023) Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma. Neuro Oncol 25(11):2058\u20132071. https:\/\/doi.org\/10.1093\/neuonc\/noad087","journal-title":"Neuro Oncol"},{"issue":"14","key":"4106_CR79","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","volume":"363","author":"AL Yu","year":"2010","unstructured":"Yu AL, Gilman AL, Ozkaynak MF et al (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363(14):1324\u20131334. https:\/\/doi.org\/10.1056\/NEJMoa0911123","journal-title":"N Engl J Med"},{"issue":"11","key":"4106_CR80","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.1882","volume":"14","author":"MA Pule","year":"2008","unstructured":"Pule MA, Savoldo B, Myers GD et al (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14(11):1264\u20131270. https:\/\/doi.org\/10.1038\/nm.1882","journal-title":"Nat Med"},{"issue":"2","key":"4106_CR81","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.stemcr.2022.12.012","volume":"18","author":"J Zhang","year":"2023","unstructured":"Zhang J, Webster S, Duffin B et al (2023) Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies. Stem Cell Reports 18(2):585\u2013596. https:\/\/doi.org\/10.1016\/j.stemcr.2022.12.012","journal-title":"Stem Cell Reports"},{"key":"4106_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1145706","volume":"14","author":"P Zuo","year":"2023","unstructured":"Zuo P, Li Y, He C et al (2023) Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas. Front Immunol 14:1145706. https:\/\/doi.org\/10.3389\/fimmu.2023.1145706","journal-title":"Front Immunol"},{"issue":"10","key":"4106_CR83","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrc3144","volume":"11","author":"S Vaughan","year":"2011","unstructured":"Vaughan S, Coward JI, Bast RC Jr et al (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11(10):719\u2013725. https:\/\/doi.org\/10.1038\/nrc3144","journal-title":"Nat Rev Cancer"},{"key":"4106_CR84","doi-asserted-by":"publisher","DOI":"10.3892\/or.2024.8709","author":"Y Hou","year":"2024","unstructured":"Hou Y, Zhao X, Nie X (2024) Enhancing the therapeutic efficacy of NK cells in the treatment of ovarian cancer (Review). Oncol Rep. https:\/\/doi.org\/10.3892\/or.2024.8709","journal-title":"Oncol Rep"},{"issue":"1","key":"4106_CR85","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bbrc.2020.01.053","volume":"524","author":"B Cao","year":"2020","unstructured":"Cao B, Liu M, Wang L et al (2020) Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer. Biochem Biophys Res Commun 524(1):96\u2013102. https:\/\/doi.org\/10.1016\/j.bbrc.2020.01.053","journal-title":"Biochem Biophys Res Commun"},{"key":"4106_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030660","author":"R Klapdor","year":"2019","unstructured":"Klapdor R, Wang S, Morgan M et al (2019) Characterization of a novel third-generation anti-CD24-CAR against ovarian cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20030660","journal-title":"Int J Mol Sci"},{"issue":"8","key":"4106_CR87","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/cji.0000000000000286","volume":"42","author":"X Ao","year":"2019","unstructured":"Ao X, Yang Y, Li W et al (2019) Anti-\u03b1FR CAR-engineered NK-92 cells display potent cytotoxicity against \u03b1FR-positive ovarian cancer. J Immunother 42(8):284\u2013296. https:\/\/doi.org\/10.1097\/cji.0000000000000286","journal-title":"J Immunother"},{"issue":"30","key":"4106_CR88","doi-asserted-by":"publisher","first-page":"6876","DOI":"10.3748\/wjg.v22.i30.6876","volume":"22","author":"T Hu","year":"2016","unstructured":"Hu T, Li Z, Gao CY et al (2016) Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World J Gastroenterol 22(30):6876\u20136889. https:\/\/doi.org\/10.3748\/wjg.v22.i30.6876","journal-title":"World J Gastroenterol"},{"issue":"8","key":"4106_CR89","doi-asserted-by":"publisher","first-page":"13545","DOI":"10.18632\/oncotarget.14592","volume":"8","author":"WX Ang","year":"2017","unstructured":"Ang WX, Li Z, Chi Z et al (2017) Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis. Oncotarget 8(8):13545\u201313559. https:\/\/doi.org\/10.18632\/oncotarget.14592","journal-title":"Oncotarget"},{"key":"4106_CR90","doi-asserted-by":"publisher","first-page":"4263520","DOI":"10.1155\/2018\/4263520","volume":"2018","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Zhang H, Ding J et al (2018) Combination therapy with EpCAM-CAR-NK-92 cells and regorafenib against human colorectal cancer models. J Immunol Res 2018:4263520. https:\/\/doi.org\/10.1155\/2018\/4263520","journal-title":"J Immunol Res"},{"issue":"1","key":"4106_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-018-0262-z","volume":"19","author":"M Shiozawa","year":"2018","unstructured":"Shiozawa M, Chang CH, Huang YC et al (2018) Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells. BMC Immunol 19(1):27. https:\/\/doi.org\/10.1186\/s12865-018-0262-z","journal-title":"BMC Immunol"},{"key":"4106_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020388","author":"AS Franz\u00e9n","year":"2024","unstructured":"Franz\u00e9n AS, Boulifa A, Radecke C et al (2024) Next-generation CEA-CAR-NK-92 cells against solid tumors: overcoming tumor microenvironment challenges in colorectal cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16020388","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4106_CR93","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.path.2019.11.002","volume":"13","author":"R Ruiz-Cordero","year":"2020","unstructured":"Ruiz-Cordero R, Devine WP (2020) Targeted therapy and checkpoint immunotherapy in lung cancer. Surg Pathol Clin 13(1):17\u201333. https:\/\/doi.org\/10.1016\/j.path.2019.11.002","journal-title":"Surg Pathol Clin"},{"issue":"4","key":"4106_CR94","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/jlb.5ma0122-467r","volume":"112","author":"M Liu","year":"2022","unstructured":"Liu M, Huang W, Guo Y et al (2022) CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo. J Leukoc Biol 112(4):901\u2013911. https:\/\/doi.org\/10.1002\/jlb.5ma0122-467r","journal-title":"J Leukoc Biol"},{"key":"4106_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106656","volume":"188","author":"Y Peng","year":"2023","unstructured":"Peng Y, Zhang W, Chen Y et al (2023) Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma. Pharmacol Res 188:106656. https:\/\/doi.org\/10.1016\/j.phrs.2023.106656","journal-title":"Pharmacol Res"},{"issue":"1","key":"4106_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11806-1","volume":"24","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zhang C, He M et al (2024) Co-expression of IL-21-enhanced NKG2D CAR-NK cell therapy for lung cancer. BMC Cancer 24(1):119. https:\/\/doi.org\/10.1186\/s12885-023-11806-1","journal-title":"BMC Cancer"},{"issue":"6","key":"4106_CR97","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21161","volume":"62","author":"M Maluccio","year":"2012","unstructured":"Maluccio M, Covey A (2012) Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 62(6):394\u2013399. https:\/\/doi.org\/10.3322\/caac.21161","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"4106_CR98","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier E, Tomasello E, Baratin M et al (2008) Functions of natural killer cells. Nat Immunol 9(5):503\u2013510. https:\/\/doi.org\/10.1038\/ni1582","journal-title":"Nat Immunol"},{"issue":"24","key":"4106_CR99","doi-asserted-by":"publisher","first-page":"6418","DOI":"10.1158\/1078-0432.Ccr-14-1170","volume":"20","author":"H Gao","year":"2014","unstructured":"Gao H, Li K, Tu H et al (2014) Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res 20(24):6418\u20136428. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-1170","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4106_CR100","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ymthe.2017.12.012","volume":"26","author":"M Yu","year":"2018","unstructured":"Yu M, Luo H, Fan M et al (2018) Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma. Mol Ther 26(2):366\u2013378. https:\/\/doi.org\/10.1016\/j.ymthe.2017.12.012","journal-title":"Mol Ther"},{"issue":"1","key":"4106_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18444-2","volume":"11","author":"HC Tseng","year":"2020","unstructured":"Tseng HC, Xiong W, Badeti S et al (2020) Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun 11(1):4810. https:\/\/doi.org\/10.1038\/s41467-020-18444-2","journal-title":"Nat Commun"},{"issue":"1","key":"4106_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-022-00822-6","volume":"12","author":"S Badeti","year":"2022","unstructured":"Badeti S, Jiang Q, Naghizadeh A et al (2022) Development of a novel human CD147 knock-in NSG mouse model to test SARS-CoV-2 viral infection. Cell Biosci 12(1):88. https:\/\/doi.org\/10.1186\/s13578-022-00822-6","journal-title":"Cell Biosci"},{"issue":"1","key":"4106_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.200957","volume":"33","author":"Y Sabha","year":"2025","unstructured":"Sabha Y, Kim SH, Tseng HC et al (2025) CD147-CAR-NK cell therapy shows minimal toxicities in human CD147 transgenic mouse model with solid tumors. Mol Ther Oncolytics 33(1):200957. https:\/\/doi.org\/10.1016\/j.omton.2025.200957","journal-title":"Mol Ther Oncolytics"},{"issue":"649","key":"4106_CR104","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg4132","volume":"14","author":"M Sawant","year":"2022","unstructured":"Sawant M, Mahajan K, Renganathan A et al (2022) Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting. Sci Transl Med 14(649):eabg4132. https:\/\/doi.org\/10.1126\/scitranslmed.abg4132","journal-title":"Sci Transl Med"},{"key":"4106_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061382","author":"IM Montagner","year":"2020","unstructured":"Montagner IM, Penna A, Fracasso G et al (2020) Anti-PSMA CAR-engineered NK-92 cells: an off-the-shelf cell therapy for prostate cancer. Cells. https:\/\/doi.org\/10.3390\/cells9061382","journal-title":"Cells"},{"key":"4106_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21082956","author":"R Corchado-Cobos","year":"2020","unstructured":"Corchado-Cobos R, Garc\u00eda-Sancha N, Gonz\u00e1lez-Sarmiento R et al (2020) Cutaneous squamous cell carcinoma: from biology to therapy. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21082956","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4106_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hoc.2018.08.001","volume":"33","author":"A Waldman","year":"2019","unstructured":"Waldman A, Schmults C (2019) Cutaneous squamous cell carcinoma. Hematol Oncol Clin North Am 33(1):1\u201312. https:\/\/doi.org\/10.1016\/j.hoc.2018.08.001","journal-title":"Hematol Oncol Clin North Am"},{"key":"4106_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1337489","volume":"15","author":"X Lin","year":"2024","unstructured":"Lin X, Guan T, Xu Y et al (2024) Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted CAR-NK cells against human esophageal squamous cell carcinoma. Front Immunol 15:1337489. https:\/\/doi.org\/10.3389\/fimmu.2024.1337489","journal-title":"Front Immunol"},{"issue":"1","key":"4106_CR109","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0650-7","volume":"16","author":"Q Liu","year":"2017","unstructured":"Liu Q, Cui X, Yu X et al (2017) Cripto-1 acts as a functional marker of cancer stem-like cells and predicts prognosis of the patients in esophageal squamous cell carcinoma. Mol Cancer 16(1):81. https:\/\/doi.org\/10.1186\/s12943-017-0650-7","journal-title":"Mol Cancer"},{"issue":"1","key":"4106_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04409-8","volume":"21","author":"T Liu","year":"2023","unstructured":"Liu T, Dai X, Xu Y et al (2023) CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma. J Transl Med 21(1):710. https:\/\/doi.org\/10.1186\/s12967-023-04409-8","journal-title":"J Transl Med"},{"key":"4106_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1337557","volume":"15","author":"X Lin","year":"2024","unstructured":"Lin X, Guan T, Li Y et al (2024) Efficacy of MUC1-targeted CAR-NK cells against human tongue squamous cell carcinoma. Front Immunol 15:1337557. https:\/\/doi.org\/10.3389\/fimmu.2024.1337557","journal-title":"Front Immunol"},{"key":"4106_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez M, Moon EK (2019) CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol 10:128. https:\/\/doi.org\/10.3389\/fimmu.2019.00128","journal-title":"Front Immunol"},{"key":"4106_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00045","volume":"8","author":"A Ager","year":"2017","unstructured":"Ager A (2017) High endothelial venules and other blood vessels: critical regulators of lymphoid organ development and function. Front Immunol 8:45. https:\/\/doi.org\/10.3389\/fimmu.2017.00045","journal-title":"Front Immunol"},{"issue":"5","key":"4106_CR114","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","volume":"146","author":"CW Freyer","year":"2020","unstructured":"Freyer CW, Porter DL (2020) Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol 146(5):940\u2013948. https:\/\/doi.org\/10.1016\/j.jaci.2020.07.025","journal-title":"J Allergy Clin Immunol"},{"issue":"26","key":"4106_CR115","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127(26):3321\u20133330. https:\/\/doi.org\/10.1182\/blood-2016-04-703751","journal-title":"Blood"},{"key":"4106_CR116","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147652","author":"M Cosenza","year":"2021","unstructured":"Cosenza M, Sacchi S, Pozzi S (2021) Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22147652","journal-title":"Int J Mol Sci"},{"issue":"9967","key":"4106_CR117","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/s0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385(9967):517\u2013528. https:\/\/doi.org\/10.1016\/s0140-6736(14)61403-3","journal-title":"Lancet"},{"issue":"26","key":"4106_CR118","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"4106_CR119","doi-asserted-by":"publisher","first-page":"1190379","DOI":"10.3389\/fimmu.2023.1190379","volume":"14","author":"D Shah","year":"2023","unstructured":"Shah D, Soper B, Shopland L (2023) Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures. Front Immunol 14:1190379. https:\/\/doi.org\/10.3389\/fimmu.2023.1190379","journal-title":"Front Immunol"},{"key":"4106_CR120","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577027","volume":"11","author":"J Gust","year":"2020","unstructured":"Gust J, Ponce R, Liles WC et al (2020) Cytokines in CAR T cell-associated neurotoxicity. Front Immunol 11:577027. https:\/\/doi.org\/10.3389\/fimmu.2020.577027","journal-title":"Front Immunol"},{"issue":"10","key":"4106_CR121","doi-asserted-by":"publisher","first-page":"of2","DOI":"10.1158\/2159-8290.Cd-nb2017-124","volume":"7","author":"A Poh","year":"2017","unstructured":"Poh A(2017) Equipping NK Cells with CARs. Cancer Discov 7(10):of2. https:\/\/doi.org\/10.1158\/2159-8290.Cd-nb2017-124","journal-title":"Cancer Discov"},{"key":"4106_CR122","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3389\/fimmu.2018.00283","volume":"9","author":"RS Mehta","year":"2018","unstructured":"Mehta RS, Rezvani K (2018) Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer. Front Immunol 9:283. https:\/\/doi.org\/10.3389\/fimmu.2018.00283","journal-title":"Front Immunol"},{"issue":"8","key":"4106_CR123","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","volume":"25","author":"K Rezvani","year":"2017","unstructured":"Rezvani K, Rouce R, Liu E et al (2017) Engineering natural killer cells for cancer immunotherapy. Mol Ther 25(8):1769\u20131781. https:\/\/doi.org\/10.1016\/j.ymthe.2017.06.012","journal-title":"Mol Ther"},{"issue":"6","key":"4106_CR124","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","volume":"27","author":"L Xiao","year":"2019","unstructured":"Xiao L, Cen D, Gan H et al (2019) Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients. Mol Ther 27(6):1114\u20131125. https:\/\/doi.org\/10.1016\/j.ymthe.2019.03.011","journal-title":"Mol Ther"},{"issue":"3","key":"4106_CR125","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/cmi.2014.91","volume":"12","author":"C Sun","year":"2015","unstructured":"Sun C, Sun H, Zhang C et al (2015) NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol 12(3):292\u2013302. https:\/\/doi.org\/10.1038\/cmi.2014.91","journal-title":"Cell Mol Immunol"},{"issue":"10","key":"4106_CR126","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/aps.2015.41","volume":"36","author":"C Sun","year":"2015","unstructured":"Sun C, Sun HY, Xiao WH et al (2015) Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy. Acta Pharmacol Sin 36(10):1191\u20131199. https:\/\/doi.org\/10.1038\/aps.2015.41","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"4106_CR127","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood-2005-04-1351","volume":"107","author":"YT Bryceson","year":"2006","unstructured":"Bryceson YT, March ME, Ljunggren HG et al (2006) Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107(1):159\u2013166. https:\/\/doi.org\/10.1182\/blood-2005-04-1351","journal-title":"Blood"},{"issue":"6013","key":"4106_CR128","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","volume":"331","author":"E Vivier","year":"2011","unstructured":"Vivier E, Raulet DH, Moretta A et al (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331(6013):44\u201349. https:\/\/doi.org\/10.1126\/science.1198687","journal-title":"Science"},{"issue":"4","key":"4106_CR129","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/stem.1611","volume":"32","author":"Z Ni","year":"2014","unstructured":"Ni Z, Knorr DA, Bendzick L et al (2014) Expression of chimeric receptor CD4\u03b6 by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. Stem Cells 32(4):1021\u20131031. https:\/\/doi.org\/10.1002\/stem.1611","journal-title":"Stem Cells"},{"issue":"7","key":"4106_CR130","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/jcmm.12810","volume":"20","author":"A Romanski","year":"2016","unstructured":"Romanski A, Uherek C, Bug G et al (2016) CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med 20(7):1287\u20131294. https:\/\/doi.org\/10.1111\/jcmm.12810","journal-title":"J Cell Mol Med"},{"issue":"2","key":"4106_CR131","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1007\/s12024-023-00693-4","volume":"20","author":"C Zhao","year":"2024","unstructured":"Zhao C, Zhang L, Zheng Z et al (2024) Case report: sudden death following the administration of CAR-NK cells for lung cancer immunotherapy. Forensic Sci Med Pathol 20(2):690\u2013695. https:\/\/doi.org\/10.1007\/s12024-023-00693-4","journal-title":"Forensic Sci Med Pathol"},{"issue":"2","key":"4106_CR132","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu E, Tong Y, Dotti G et al (2018) Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32(2):520\u2013531. https:\/\/doi.org\/10.1038\/leu.2017.226","journal-title":"Leukemia"},{"issue":"7","key":"4106_CR133","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.ymthe.2024.05.022","volume":"32","author":"T Bexte","year":"2024","unstructured":"Bexte T, Botezatu L, Miskey C et al (2024) Engineering of potent CAR NK cells using non-viral sleeping beauty transposition from minimalistic DNA vectors. Mol Ther 32(7):2357\u20132372. https:\/\/doi.org\/10.1016\/j.ymthe.2024.05.022","journal-title":"Mol Ther"},{"issue":"3","key":"4106_CR134","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L (2020) PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res 10(3):727\u2013742","journal-title":"Am J Cancer Res"},{"issue":"1","key":"4106_CR135","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-02077-1","volume":"10","author":"Y Zhong","year":"2024","unstructured":"Zhong Y, Liu J (2024) Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions. Cell Death Discov 10(1):318. https:\/\/doi.org\/10.1038\/s41420-024-02077-1","journal-title":"Cell Death Discov"},{"issue":"1","key":"4106_CR136","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","volume":"10","author":"W Wang","year":"2024","unstructured":"Wang W, Liu Y, He Z et al (2024) Breakthrough of solid tumor treatment: CAR-NK immunotherapy. Cell Death Discov 10(1):40. https:\/\/doi.org\/10.1038\/s41420-024-01815-9","journal-title":"Cell Death Discov"},{"issue":"9","key":"4106_CR137","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.stem.2024.06.009","volume":"31","author":"JL Thangaraj","year":"2024","unstructured":"Thangaraj JL, Coffey M, Lopez E et al (2024) Disruption of TGF-\u03b2 signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells. Cell Stem Cell 31(9):1327-1343.e5. https:\/\/doi.org\/10.1016\/j.stem.2024.06.009","journal-title":"Cell Stem Cell"},{"issue":"11","key":"4106_CR138","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202303963","volume":"13","author":"J Duan","year":"2024","unstructured":"Duan J, Zhao S, Duan Y et al (2024) Mno(x) nanoenzyme armed CAR-NK cells enhance solid tumor immunotherapy by alleviating the immunosuppressive microenvironment. Adv Healthc Mater 13(11):e2303963. https:\/\/doi.org\/10.1002\/adhm.202303963","journal-title":"Adv Healthc Mater"},{"issue":"3","key":"4106_CR139","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/s41591-023-02770-1","volume":"30","author":"Y Li","year":"2024","unstructured":"Li Y, Basar R, Wang G et al (2024) Author correction: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med 30(3):906. https:\/\/doi.org\/10.1038\/s41591-023-02770-1","journal-title":"Nat Med"},{"key":"4106_CR140","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.S253565","author":"Y Huang","year":"2020","unstructured":"Huang Y, Zeng J, Liu T et al (2020) DNAM1 and 2B4 costimulatory domains enhance the cytotoxicity of anti-GPC3 chimeric antigen receptor-modified natural killer cells against hepatocellular cancer cells in vitro. Cancer Manag Res. https:\/\/doi.org\/10.2147\/cmar.S253565","journal-title":"Cancer Manag Res"},{"key":"4106_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02282-4","author":"L Peng","year":"2024","unstructured":"Peng L, Renauer PA, Sferruzza G et al (2024) In vivo AAV-SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy. Nat Biotechnol. https:\/\/doi.org\/10.1038\/s41587-024-02282-4","journal-title":"Nat Biotechnol"},{"key":"4106_CR142","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003894","author":"I Christodoulou","year":"2021","unstructured":"Christodoulou I, Ho WJ, Marple A et al (2021) Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-003894","journal-title":"J Immunother Cancer"},{"issue":"7750","key":"4106_CR143","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh M, Dobrin A, Cabriolu A et al (2019) CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568(7750):112\u2013116. https:\/\/doi.org\/10.1038\/s41586-019-1054-1","journal-title":"Nature"},{"issue":"6","key":"4106_CR144","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","volume":"173","author":"JH Cho","year":"2018","unstructured":"Cho JH, Collins JJ, Wong WW (2018) Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173(6):1426-1438.e11. https:\/\/doi.org\/10.1016\/j.cell.2018.03.038","journal-title":"Cell"},{"key":"4106_CR145","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe7378","author":"JH Choe","year":"2021","unstructured":"Choe JH, Watchmaker PB, Simic MS et al (2021) Synnotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.abe7378","journal-title":"Sci Transl Med"},{"issue":"1","key":"4106_CR146","doi-asserted-by":"publisher","first-page":"7222","DOI":"10.1038\/s41467-024-51694-y","volume":"15","author":"R Chen","year":"2024","unstructured":"Chen R, Shi X, Yao X et al (2024) Specific multivalent molecules boost CRISPR-mediated transcriptional activation. Nat Commun 15(1):7222. https:\/\/doi.org\/10.1038\/s41467-024-51694-y","journal-title":"Nat Commun"},{"key":"4106_CR147","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/978-1-0716-3445-5_15","volume":"2715","author":"JS Lin","year":"2024","unstructured":"Lin JS, Lai EM (2024) Protein-Protein Interactions: Yeast Two Hybrid. Methods Mol Biol 2715:235\u2013246. https:\/\/doi.org\/10.1007\/978-1-0716-3445-5_15","journal-title":"Methods Mol Biol"},{"issue":"6","key":"4106_CR148","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1158\/0008-5472.Can-23-1237","volume":"84","author":"F Martins","year":"2024","unstructured":"Martins F, Rosspopoff O, Carlevaro-Fita J et al (2024) A cluster of evolutionarily recent KRAB zinc finger proteins protects cancer cells from replicative stress-induced inflammation. Cancer Res 84(6):808\u2013826. https:\/\/doi.org\/10.1158\/0008-5472.Can-23-1237","journal-title":"Cancer Res"},{"issue":"1","key":"4106_CR149","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-024-01828-x","volume":"9","author":"Q Shi","year":"2024","unstructured":"Shi Q, Xue C, Zeng Y et al (2024) Notch signaling pathway in cancer: from mechanistic insights to targeted therapies. Signal Transduct Target Ther 9(1):128. https:\/\/doi.org\/10.1038\/s41392-024-01828-x","journal-title":"Signal Transduct Target Ther"},{"key":"4106_CR150","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd8836","author":"A Hyrenius-Wittsten","year":"2021","unstructured":"Hyrenius-Wittsten A, Su Y, Park M et al (2021) Synnotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.abd8836","journal-title":"Sci Transl Med"},{"issue":"1","key":"4106_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20785-x","volume":"12","author":"B Moghimi","year":"2021","unstructured":"Moghimi B, Muthugounder S, Jambon S et al (2021) Preclinical assessment of the efficacy and specificity of GD2-B7H3 synnotch CAR-T in metastatic neuroblastoma. Nat Commun 12(1):511. https:\/\/doi.org\/10.1038\/s41467-020-20785-x","journal-title":"Nat Commun"},{"issue":"6520","key":"4106_CR152","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1126\/science.abc6270","volume":"370","author":"JZ Williams","year":"2020","unstructured":"Williams JZ, Allen GM, Shah D et al (2020) Precise T cell recognition programs designed by transcriptionally linking multiple receptors. Science 370(6520):1099\u20131104. https:\/\/doi.org\/10.1126\/science.abc6270","journal-title":"Science"},{"issue":"8","key":"4106_CR153","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1016\/j.ymthe.2024.06.023","volume":"32","author":"M Cortese","year":"2024","unstructured":"Cortese M, Torchiaro E, D\u2019Andrea A et al (2024) Preclinical efficacy of a HER2 synNotch\/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification. Mol Ther 32(8):2741\u20132761. https:\/\/doi.org\/10.1016\/j.ymthe.2024.06.023","journal-title":"Mol Ther"},{"key":"4106_CR154","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006130","author":"YE Lee","year":"2023","unstructured":"Lee YE, Go GY, Koh EY et al (2023) Synergistic therapeutic combination with a CAF inhibitor enhances CAR-NK-mediated cytotoxicity via reduction of CAF-released IL-6. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-006130","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4106_CR155","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40457-w","volume":"14","author":"Y Huang","year":"2023","unstructured":"Huang Y, Mohanty V, Dede M et al (2023) Characterizing cancer metabolism from bulk and single-cell RNA-seq data using METAFlux. Nat Commun 14(1):4883. https:\/\/doi.org\/10.1038\/s41467-023-40457-w","journal-title":"Nat Commun"},{"key":"4106_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.12.057","author":"H Hosseinalizadeh","year":"2025","unstructured":"Hosseinalizadeh H, Wang LS, Mirzaei H et al (2025) Emerging combined CAR-NK cell therapies in cancer treatment: finding a dancing partner. Mol Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2024.12.057","journal-title":"Mol Ther"},{"issue":"5","key":"4106_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27196","volume":"10","author":"J Li","year":"2024","unstructured":"Li J, Hu H, Lian K et al (2024) CAR-NK cells in combination therapy against cancer: a potential paradigm. Heliyon 10(5):e27196. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27196","journal-title":"Heliyon"},{"issue":"1","key":"4106_CR158","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46343-3","volume":"15","author":"KB Lupo","year":"2024","unstructured":"Lupo KB, Yao X, Borde S et al (2024) Synnotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy. Nat Commun 15(1):1909. https:\/\/doi.org\/10.1038\/s41467-024-46343-3","journal-title":"Nat Commun"},{"issue":"4","key":"4106_CR159","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.3390\/cimb46040183","volume":"46","author":"A Ahmadnia","year":"2024","unstructured":"Ahmadnia A, Mohammadi S, Yamchi A et al (2024) Augmenting the antitumor efficacy of natural killer cells via synnotch receptor engineering for targeted IL-12 secretion. Curr Issues Mol Biol 46(4):2931\u20132945. https:\/\/doi.org\/10.3390\/cimb46040183","journal-title":"Curr Issues Mol Biol"},{"key":"4106_CR160","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.14.426742","author":"M Ma","year":"2021","unstructured":"Ma M, Badeti S, Chen CH et al (2021) CAR-NK cells effectively target the D614 and G614 SARS-CoV-2 infected cells. BioRxiv. https:\/\/doi.org\/10.1101\/2021.01.14.426742","journal-title":"BioRxiv"},{"issue":"9","key":"4106_CR161","doi-asserted-by":"publisher","first-page":"14812","DOI":"10.1002\/jcp.28280","volume":"234","author":"A Mazarzaei","year":"2019","unstructured":"Mazarzaei A, Vafaei M, Ghasemian A et al (2019) Memory and CAR-NK cell-based novel approaches for HIV vaccination and eradication. J Cell Physiol 234(9):14812\u201314817. https:\/\/doi.org\/10.1002\/jcp.28280","journal-title":"J Cell Physiol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04106-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04106-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04106-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:03:11Z","timestamp":1758729791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04106-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":161,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["4106"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04106-z","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors have read and approved the manuscript and consent to its publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"275"}}